SCHEMBL4707663

SCHEMBL4707663

CCn1nc(-c2ccc(F)cc2)c(C(C)=O)c(Nc2ccc(CO)cc2)c1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.64
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HTR1A P08908 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
PKM P14618 1/20 0.37
BLM P54132 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
FPR1 P21462 1/20 0.36
FPR2 P25090 1/20 0.36
ACHE P22303 1/20 0.36
BACE1 P56817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708476 0.90 PDE4B (0.79) PDE4BSMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL3028282 0.89 PDE4B (0.65) PDE4BMAPTSMN1; SMN2HTR1AADRA1D
SCHEMBL4707416 0.89 PDE4B (0.80) PDE4BMAPTSMN1; SMN2HTR1AADRA1D
SCHEMBL4707445 0.88 PDE4B (0.62) PDE4BSMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL4708670 0.87 PDE4B (0.63) PDE4BMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL4049559 0.84 PDE4B (0.44) PDE4BMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL3039540 0.83 PDE4B (0.63) PDE4BSMN1; SMN2ALDH1A1
SCHEMBL1653661 0.83 PDE4B (0.55) PDE4BMAPTKDM4EPKMFPR1
SCHEMBL4706133 0.83 PDE4B (0.85) PDE4BSMN1; SMN2HTR1AADRA1DADRA1A
SCHEMBL4709069 0.82 PDE4B (0.62) PDE4BHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885MAPT 3692/4885SMN1; SMN2 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.